Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Matthew Gillmor CFA
KEY
Matthew Gillmor CFA
KeyBanc
Wall Street Analyst
★★★☆☆
#965
on 13Foresight · ranked by our own returns
50%
Success Rate
+5.8%
Average Return
10 of 20 calls profitable · +0.4% vs benchmark
📈 Across the calls we could measure, roughly 50% of Matthew Gillmor CFA's ratings turned a profit when each position was held for 1 year — averaging +5.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

45 Buy 18 Hold 0 Sell
Matthew's Stock Coverage 17 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
EHC
Encompass Health
 Jun 12, 2026 BUY Strong Buy
+13.4% avg upside
22 analysts
 — -3.5%
ALHC
Alignment Healthcare
 Jun 10, 2026 BUY Strong Buy
+1.8% avg upside
19 analysts
$28.00
30.71% Upside
 -4.4%
ARDT
Ardent Health Partners, Inc.
 Jun 03, 2026 HOLD Buy
+52.6% avg upside
16 analysts
 — +16.0%
EVH
Evolent Health
 May 08, 2026 HOLD Strong Buy
+121.1% avg upside
19 analysts
 — +1.0%
ADUS
Addus Homecare
 May 07, 2026 BUY Strong Buy
+35.9% avg upside
18 analysts
 — -4.0%
SGRY
Surgery Partners
 May 06, 2026 HOLD Strong Buy
+69.2% avg upside
18 analysts
 — +3.8%
BTSG
BrightSpring Health Services, Inc.
 May 04, 2026 BUY Strong Buy
-16.1% avg upside
18 analysts
$60.00
6.90% Downside
 +20.3%
THC
Tenet Healthcare
 May 01, 2026 BUY Strong Buy
+25.2% avg upside
26 analysts
$225.00
25.99% Upside
 -2.6%
HUM
Humana
 Apr 30, 2026 HOLD Buy
-11.2% avg upside
34 analysts
 — +53.1%
RDNT
Radnet
 Apr 29, 2026 BUY Strong Buy
+50.1% avg upside
10 analysts
$92.00
74.19% Upside
 +1.1%
HCA
HCA Healthcare
 Apr 27, 2026 BUY Buy
+14.2% avg upside
35 analysts
$510.00
31.37% Upside
 -12.8%
UNH
UnitedHealth
 Apr 22, 2026 BUY Strong Buy
+2.4% avg upside
35 analysts
$400.00
0.10% Upside
 +16.0%
INNV
InnovAge Holding
 Mar 06, 2026 HOLD Sell
-19.2% avg upside
12 analysts
 — -20.7%
ASTH
Astrana Health
 Mar 03, 2026 HOLD Strong Buy
+37.0% avg upside
16 analysts
 — +55.7%
PRVA
Privia Health Group
 Feb 27, 2026 BUY Strong Buy
+34.1% avg upside
26 analysts
 — -8.9%
ACHC
Acadia Healthcare
 Dec 03, 2025 BUY Strong Buy
+57.2% avg upside
17 analysts
$25.00
6.39% Upside
 +60.0%
UHS
Universal Health
 Oct 28, 2025 HOLD Buy
+50.4% avg upside
22 analysts
 — -35.4%
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Matthew Gillmor CFA — Frequently Asked Questions
How accurate are Matthew Gillmor CFA's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Matthew's ratings were profitable over a one-year hold, with an average return of +5.8% per rating, or +0.4% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Matthew ranked on 13Foresight?
Matthew Gillmor CFA is currently ranked #965 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Matthew cover?
Matthew most recently has ratings on EHC, ALHC, ARDT, EVH, ADUS, SGRY, BTSG, THC, HUM, RDNT, HCA, UNH and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.